Published on 9 Mar 2022 on Zacks via Yahoo Finance
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
BioNTech SE BNTX announced that it has expanded its current strategic collaboration agreement with Regeneron Pharmaceuticals REGN to begin a third cancer study.
With the expanded agreement, BioNTech is looking to evaluate its FixVac candidate, BNT116, in combination with Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the treatment of patients with advanced non-small-cell lung cancer (“NSCLC”), the most common type of lung cancer.
Per the latest agreement, BioNTech and Regeneron will equally share all development costs for the studies on the combo of BNT116 plus Libtayo. The companies are planning to begin a phase I/II study evaluating BNT116 plus Libtayo in the first-line treatment setting for advanced NSCLC.